ADMA Biologics (ADMA) Q2 2026 earnings review
ASCENIV Growth Offsets Standard IG Pressures, Hinting at Steep H2 Acceleration
ADMA managed a 2% YoY revenue growth in Q2, driven by a 24% surge in its high-margin ASCENIV product, which effectively offset a 49% collapse in BIVIGAM sales. The company's yield enhancement initiatives and favorable product mix drove gross margins to a structural new level of 69% (up from 55% a year ago). BIVIGAM showed early signs of sequential stabilization, bouncing off its Q1 trough. Management reiterated full-year revenue guidance of $530-$560 million. With first-half revenue at $238.9 million, achieving the midpoint implies a steep acceleration in the second half of the year.
🐂 Bull Case
ASCENIV is proving highly resilient to the U.S. standard IG pricing wars. Record end-market demand and accelerating month-over-month utilization indicate the product remains early in its penetration curve.
The successful rollout of FDA-approved yield enhancements has radically shifted the company's profitability profile, allowing 69% gross margins and massive operating cash flow generation to fund aggressive buybacks.
🐻 Bear Case
Despite sequential stabilization, BIVIGAM revenues are still down 49% YoY due to persistent oversupply and 15-20% ASP discounting by competitors in the standard IG market.
Reiterating annual guidance means the company must deliver roughly $153 million per quarter in H2 (compared to $124.4M in Q2), representing a steep sequential acceleration reliant on uninterrupted ASCENIV growth.
⚖️ Verdict: 🟢
Bullish. While the standard IG market remains a headwind, ASCENIV has proven it is fully insulated. The business is generating massive cash flows, structurally expanding margins, and repurchasing equity at a rapid clip.
Key Themes
Real-World Evidence Differentiates ASCENIV
Management is actively building the moat around ASCENIV. An abstract submitted to the ACAAI highlighting 127 real-world patients showed statistically significant reductions in infection-related hospitalizations, oral antibiotic use, and corticosteroid use post-ASCENIV administration. This clinical differentiation is critical to insulating the product from standard IG pricing wars and sustaining its accelerating adoption.
Yield Enhancements Flowing to the Bottom Line
The FDA-approved yield enhancement process continues to generate significant leverage. Gross margin expanded from 55% in 25Q2 to 69% in 26Q2. This stable, elevated margin profile ensures that as ASCENIV mix grows, gross profit outpaces top-line growth, generating the cash needed for aggressive share repurchases.
BIVIGAM Shows Sequential Stabilization
While BIVIGAM remains a major year-over-year drag, it is showing signs of sequential stabilization. Sales recovered to $19.4M in 26Q2 from the $15.4M trough in 26Q1. This suggests the worst of the distributor destocking and aggressive competitor price-matching shocks may have passed, though the broader macro headwind of U.S. standard IG oversupply remains.
SG-001 Investment and SG&A Drag
Operating expenses are accelerating, offsetting some of the gross margin gains. R&D jumped 6x YoY to $6.0M as the company accelerates SG-001 preclinical and conformance lot production ahead of a pre-IND meeting. Concurrently, SG&A increased 20% YoY to $26.7M due to higher headcount and legal/consulting fees. If the H2 revenue ramp stumbles, these fixed cost step-ups will heavily compress operating leverage.
Tax Rate Pressuring EPS
Despite a 28% increase in pre-tax income, GAAP Net Income only grew 11%. This deceleration on the bottom line was driven by a much higher effective tax rate (24.7% in 26Q2 vs. 14.7% in 25Q2), reflecting the transition to a fully taxable profile.
Other KPIs
Accelerating dramatically from $1.5 million in the first half of 2025. This massive cash generation stems from the higher ASCENIV mix and structural yield enhancements. It fully funds the company's aggressive stock repurchase program without requiring external debt.
ADMA bought back 7.1 million shares in Q2, bringing the year-to-date total to 13.8 million (5.3% of outstanding shares). The company is on track to complete its $200 million+ 2026 share repurchase target, utilizing organic cash flow while maintaining net leverage flexibility.
Guidance
Stable compared to previous guidance, but implies a steep acceleration. With $238.9M delivered in H1, the midpoint implies H2 revenue of $306.1M, requiring a quarterly average of ~$153M. This relies heavily on ASCENIV capturing significant market share in the back half of the year.
Stable. The reiteration indicates management is confident that the gross margin strength seen in H1 (69-71%) is durable enough to absorb the planned step-up in R&D and SG&A expenses.
Stable. Factors in the newly elevated effective tax rate and expected legal/professional fee run rates.
Key Questions
H2 Revenue Ramp Dependency
Your reiterated FY26 guidance implies a step-up to over $150M per quarter in H2. How much of this acceleration relies on BIVIGAM pricing recovery versus pure ASCENIV volume expansion?
SG&A Inflation and Legal Fees
SG&A increased significantly YoY, partially attributed to 'ongoing legal and related matters.' Are these costs expected to persist at this run rate through the remainder of FY26, or are they transitory?
SG-001 R&D Trajectory
With R&D up 6x YoY to support SG-001, should investors view the $6M quarterly run rate as the new baseline as you move toward and past the pre-IND submission?